Northeast Georgia Medical Center - Gainesville

The Northeast Georgia Medical Center is accredited by the Commission on Cancer of the American College of Surgeons as a Community Hospital Comprehensive Cancer Program. The Northeast Georgia Medical Center is also a member of the Georgia CORE Research Network, a statewide network of academic and community-based oncologists and researchers. The center is also accredited by the American College of Radiology (ACR). The Northeast Georgia Medical Center consists of 46 physicians across two locations. The center has board-certified physician specialists and clinical oncology professionals that provide an array of programs and services to meet the needs of cancer patients and their families. State-of-the-art radiation therapy, chemotherapy and biologic and hormone therapies are available treatment options as well as innovative techniques such as prostate seed implant therapy and sentinel node biopsy. The center provides approximately 45-50 ongoing cancer clinical trials, ensuring that patients throughout northeast Georgia have access to the latest research advances in the diagnosis and treatment of cancer. The center has a new service, Patient Navigation, which provides assistance to patients as they navigate the complex healthcare system.

Treatment Sites in Georgia

Clinical Trials in Georgia

A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Cancer Type: Unknown Primary
Study Coordinator: Trena Davis BSN, RN, CRCC - 770-219-8822


A Phase II Study With Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)
Cancer Type: Breast Cancer
Study Coordinator: Trena Davis BSN, RN, CRCC - 770-219-8822


A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Cancer Type: Lung Cancer
Study Coordinator: Trena Davis BSN, RN, CRCC - 770-219-8822


A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Cancer Type: Breast Cancer

A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Cancer Type: Breast Cancer
Study Coordinator: Trena Davis BSN, RN, CRCC - 770-219-8822


Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Cancer Type: Lung Cancer
Study Coordinator: Trena Davis BSN, RN, CRCC - 770-219-8822


EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)
Cancer Type: Eye Cancer, Lymphoma, Multiple Primaries, Non-Hodgkin Lymphoma, Solid Tumor, Unknown Primary
Study Coordinator: Trena Davis BSN, RN, CRCC - 770-219-8822


EROS: Engendering Reproductive Health within Oncologic Survivorship
Cancer Type: Unknown Primary

Phase II Randomized Study of Pelvic Radiotherapy With Versus Without Cisplatin in Patients With Recurrent Endometrial Cancer
Cancer Type: Endometrial Cancer

Phase II Randomized Study of Whole-Brain Radiotherapy With Versus Without Lapatinib Ditosylate in Patients With Brain Metastasis From HER2-Positive Breast Cancer
Cancer Type: Breast Cancer
Study Coordinator: Trena Davis BSN, RN, CRCC - 770-219-8822


Phase III Randomized Study of Adjuvant Radiation Versus Chemoradiation Therapy in Patients With Intermediate-Risk Stage I-IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy
Cancer Type: Cervical Cancer

Phase III Randomized Study of Androgen-Deprivation Therapy and High-Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Patients With Unfavorable Intermediate- or Favorable High-Risk Prostate Cancer
Cancer Type: Prostate Cancer
Study Coordinator: Trena Davis BSN, RN, CRCC - (770) 219-8822


Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiotherapy With Versus Without Adjuvant Chemotherapy in Patients With High-Risk Early-Stage Cervical Carcinoma After Radical Hysterectomy
Cancer Type: Cervical Cancer
Study Coordinator: Trena Davis BSN, RN, CRCC - 770-219-8822


Phase III Randomized Study of Three Different Thoracic Radiotherapy Regimens in Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
Cancer Type: Lung Cancer
Study Coordinator: Trena Davis BSN, RN, CRCC - 770-219-8822


Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
Cancer Type: Lung Cancer
Study Coordinator: Trena Davis BSN, RN, CRCC - 770-219-8822